Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Bumpy Q4 Could Double As Inflection Point
Tweet Send to a FriendGet Alerts HITK Hot Sheet
Price: $34.38 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 13
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 13
Trade HITK Now!
Canaccord Genuity maintains a 'Buy' on Hi Tech Pharmacal (NASDAQ: HITK) price target of $45.00.
Analyst, Randall Stanicky, said, "We are lowering fiscal Q4E EPS from $0.81 to $0.73 on a combination of lower cough and cold contribution and higher near-term SG&A spending. We see further headwinds for fiscal Q4 (week of July 9) largely due to a uniquely weak and well advertised cough and cold season. That said, the stock has pulled back - 25% YTD, and we see several drivers that can make the stock work in H2/2012 and beyond for those who can look past the quarter. We see the upcoming fiscal Q4 as an inflection with limited downside from here and make no change to our price target."
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.15 yesterday, with a 52 week range of $23.72-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Randall Stanicky, said, "We are lowering fiscal Q4E EPS from $0.81 to $0.73 on a combination of lower cough and cold contribution and higher near-term SG&A spending. We see further headwinds for fiscal Q4 (week of July 9) largely due to a uniquely weak and well advertised cough and cold season. That said, the stock has pulled back - 25% YTD, and we see several drivers that can make the stock work in H2/2012 and beyond for those who can look past the quarter. We see the upcoming fiscal Q4 as an inflection with limited downside from here and make no change to our price target."
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.15 yesterday, with a 52 week range of $23.72-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- Goldman Sachs Downgrades Aixtron (AIXG) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
